

An **MMCTV** Publication
Bio-Tech Consultants
www.biospectrumindia.com

BioSpectrum

the business of Bio & Health Sciences

Volume 17 • Issue 12 • December 2019

www.biospectrumindia.com

₹100

Total pages including cover 52

**Indigenous
Medical Devices
& Diagnostics
Industry
growing at 6 %
crosses
Rs 36,000 crore**



BioSpectrum Top Indigenous Medical Devices and Diagnostics Companies 2019*

S No	Name	Revenue for 2018-19 (in Rs crore)	Revenue for 2017-18 (in Rs crore)	Per centage growth over last year (%)	Location	State	Region
1	Transasia Bio-Medicals Ltd.	1032.5	1047	-1	Mumbai	Maharastra	West
2	Trivitron Healthcare Pvt. Ltd.	700			Chennai	Tamil Nadu	South
3	Agappe Diagnostics Ltd	181			Ernakulam	Kerala	South
4	J. Mitra & Co. Pvt. Ltd.	114			New Delhi	New Delhi	North
5	Beacon Group	98			Navsari	Gujarat	West
6	Sysmex India Pvt. Ltd.	84	70	20	Mumbai	Maharastra	West
7	Nureca Pvt. Ltd.	75			Mumbai	Maharastra	West
8	Medsorce Ozone Bio Medicals Pvt. Ltd.	69	62.5	10	Faridabad	Haryana	North
9	BioSystems Diagnostics Pvt. Ltd.	44.6	42	6	Kancheepuram	Tamil Nadu	South
10	Voxtur Bio Ltd.	36			Surat	Gujarat	West
11	Genuine Biosystem Pvt. Ltd.	35			Chennai	Tamil Nadu	South
12	Accurex Biomedical Pvt. Ltd.	33.89	38.43	-12	Mumbai	Maharastra	West
13	Reckon Diagnostics Pvt. Ltd.	26	31	-16	Vadodara	Gujarat	West
14	Rapha Diagnostics Pvt. Ltd.	22			Mumbai	Maharastra	West
15	Bhat Biotech India (P) Ltd.	20	35	-43	Bangalore	Karnataka	South
16	Recombigen Laboratories Pvt. Ltd.	18	14	29	New Delhi	New Delhi	North
17	XCyton Diagnostics Pvt. Ltd.	10			Bangalore	Karnataka	South
18	Affigenix Biosolutions Pvt Ltd	4.67	3.17	47	Bangalore	Karnataka	South
19	Leucine Rich Bio Pvt Ltd.	0.54	0.34	59	Bangalore	Karnataka	South
20	Prantae Solutions Pvt. Ltd.	0.02			Bhubaneswar	Odisha	East

* We have not covered some of the indigenous and multinational medical devices and diagnostics companies as they are unable to participate in the BioSpectrum Survey 2019

TRIVITRON HEALTHCARE PVT LTD

Chennai based healthcare technology company Triviron Healthcare Pvt Ltd generated a revenue of Rs 700 crore during the FY18-19. The year 2019 saw Triviron Healthcare enter into a strategic partnership by signing a Memorandum of Association (MoA) with the Centre for Cellular and Molecular Platforms (C-CAMP) towards co-development of world-class healthcare technologies completely indigenously under Joint Intellectual Properties. Triviron is currently working along with C-Camp to co-develop relevant technologies and devices in the fields of point-of-care testing, microfluidics, and multiplex detection, which are within the domain of expertise and of strategic interest to Triviron & C-CAMP.

Triviron Healthcare has multiple brands associated with it namely Kiran Medical Systems, Labsystems Diagnostics, Triviron Healthcare Middle East, Triviron Healthcare Africa and Bome Triviron. In July 2019, Triviron took a major leap in providing cost-effective diagnostic solutions with the launch of super-efficient clinical chemistry analyzer Nanolab 200 and 5 part differential hematology analyzer with retic - Cellenium 5D Retic. In addition, Kiran Medical Systems, the radiology division of Triviron Healthcare, introduced its innovation driven surgical imaging system and Digital Mammography system in January 2019. The FY18-19 also saw the launch of a complete portfolio of Advanced Digital X-Ray systems, DSA C-Arm, Modular Smart OT Solutions and Satin Touch Radiation Protection Products by Kiran Medical Systems. The brand has also ventured into Color Doppler Ultrasound with the launch of Kiran SonoRad V9 Color Doppler in India this year.

On the other hand, Triviron's Labsystems Diagnostics Oy, a leading brand that develops and manufactures high quality diagnostic tests for clinical laboratories and physicians, expanded its portfolio on advancing newborn screening (NBS) by launching six new high quality NBS products- Neomass AAAC Plus kit, CAH MASS Second Tier test kit, SCID-SMA Multiplex PCR kit, NS496 Plus DBS Puncher, Neonatal T4 FEIA kit and Neonatal GALT Kit, during the FY18-19.

For the coming year, Triviron is focusing on creating new manufacturing facilities in Chennai and Pune with an investment of Rs 10-15 crore, and rolling out new products that will include point-of-care devices, self-testing devices for thyroid and other disorders and deficiencies. Having a rich expertise in research and development, Triviron manufactures and distributes medical technology products to 165 countries. Incepted in 1997, the company has a network of around 1500 employees, 1200 channel partners and 9 world-class manufacturing units spread throughout the world. Triviron's diagnostics portfolio include a wide range of products such as Newborn Screening Solutions, Clinical Chemistry, Hematology, Point of Care, Rapid cards, Immunology, Clinical Electrophoresis, Histopathology, Liquid based Cytology, Digital Pathology, Molecular Diagnostics and Analytical Instruments. **BS**

02

REVENUE

₹ 700 crore



DR G S K VELU
Chairman &
Managing Director